Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | ESR1 | P03372 | 2/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | METAP2 | P50579 | 1/20 | 0.56 |
| ▸ | METAP1 | P53582 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | TOP1 | P11387 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725404 | 0.98 | KMT2A (0.76) | KMT2AMAPTSMN1; SMN2SLC6A3ESR1 | |
| Hydrochloric Acid SCHEMBL16050041 | 0.95 | KMT2A (0.73) | KMT2AMAPTSMN1; SMN2SLC6A3ESR1 | |
| Acetic Acid SCHEMBL29588064 | 0.91 | KMT2A (0.68) | KMT2AMAPTSMN1; SMN2SLC6A3ESR1 | |
| SCHEMBL27853856 | 0.89 | KMT2A (0.66) | KMT2AMAPTSMN1; SMN2SLC6A3ESR1 | |
| SCHEMBL6972608 | 0.89 | KMT2A (0.66) | KMT2AMAPTSMN1; SMN2SLC6A3ESR1 | |
| SCHEMBL1671519 | 0.87 | PRSS1 (0.66) | KMT2AMAPTSMN1; SMN2SLC6A3ESR1 | |
| SCHEMBL8205898 | 0.87 | MAPT (0.63) | KMT2AMAPTSMN1; SMN2SLC6A3ESR1 | |
| SCHEMBL5162031 | 0.87 | KMT2A (0.63) | KMT2AMAPTSMN1; SMN2SLC6A3ESR1 | |
| SCHEMBL29749397 | 0.87 | PRSS1 (0.66) | KMT2AMAPTSMN1; SMN2SLC6A3ESR1 | |
| SCHEMBL10782892 | 0.86 | MAPT (0.62) | KMT2AMAPTSMN1; SMN2SLC6A3ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685739-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| CN-112521305-B | Novel high penetration drug for treating Parkinson disease and pharmaceutical composition thereof | 苏州泰飞尔医药有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20220064157-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | PREMIER RESEARCH INTERNATIONAL, LLC | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685739-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | ABCB1, PARK7, ABCG2 | SLC6A3 34/4885KMT2A 4116/4885MAPT 351/4885 |
| US-20220064157-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | ABCB1, PARK7, SLC5A7 | SLC6A3 36/4885KMT2A 4366/4885MAPT 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.